In our search for the clinically approved RhoA inhibitors, we found that Fingolimod (FTY720) and Siponimod, which are used for the treatment of multiple sclerosis [78,79,80,81], also inhibit RhoA, expression of CX3CR1 receptors, macrophage infiltration, and chronic rejection of rodent cardiac allografts [81]. Here, RHOA is linked to multiple sclerosis.